<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	>
<channel>
	<title>Comments for The Regeneration Station</title>
	<atom:link href="http://regeneration-station.com/comments/feed/" rel="self" type="application/rss+xml" />
	<link>http://regeneration-station.com</link>
	<description>Stem cells, biomaterials, engineered tissues, and other cell-based technologies.  The guts of the Regenerative Medine industry.</description>
	<pubDate>Sat, 19 Jul 2008 16:19:56 +0000</pubDate>
	<generator>http://wordpress.org/?v=MU</generator>
		<item>
		<title>Comment on Takin&#8217; a short blog break by attilachordash</title>
		<link>http://regeneration-station.com/2008/03/01/takin-a-short-blog-break/#comment-34</link>
		<dc:creator>attilachordash</dc:creator>
		<pubDate>Wed, 12 Mar 2008 21:36:55 +0000</pubDate>
		<guid isPermaLink="false">http://regenerationstation.wordpress.com/?p=104#comment-34</guid>
		<description>I hope your new position will fit eventually to this blog. I know that the industrial biotech blogging space is still nearly empty these days but I strongly suggest continuing your blog and convince other industrial actors to start their own. Positive consequences will come in the long run.</description>
		<content:encoded><![CDATA[<p>I hope your new position will fit eventually to this blog. I know that the industrial biotech blogging space is still nearly empty these days but I strongly suggest continuing your blog and convince other industrial actors to start their own. Positive consequences will come in the long run.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Celgene Strengthens Adult Stem Cell Patent Estate by Jim H</title>
		<link>http://regeneration-station.com/2008/01/04/celgene-strengthens-adult-stem-cell-patent-estate/#comment-33</link>
		<dc:creator>Jim H</dc:creator>
		<pubDate>Thu, 28 Feb 2008 14:15:37 +0000</pubDate>
		<guid isPermaLink="false">http://regeneration-station.com/2008/01/04/celgene-strengthens-adult-stem-cell-patent-estate/#comment-33</guid>
		<description>Jon,

My provisional application, does just that:  recovers HSC and progenitor ES-like cells from a "non-exsanguinated", intact (whole) afterbirth (not just the placenta, but also cord and amnion).

Whether or not the cells derived form this method match the profile that is delineated in these patents remains to be established.</description>
		<content:encoded><![CDATA[<p>Jon,</p>
<p>My provisional application, does just that:  recovers HSC and progenitor ES-like cells from a &#8220;non-exsanguinated&#8221;, intact (whole) afterbirth (not just the placenta, but also cord and amnion).</p>
<p>Whether or not the cells derived form this method match the profile that is delineated in these patents remains to be established.</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Q Therapeutics&#8217; and Invitrogen&#8217;s Symbiotic Relationship by jrowley</title>
		<link>http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/#comment-32</link>
		<dc:creator>jrowley</dc:creator>
		<pubDate>Mon, 25 Feb 2008 23:31:38 +0000</pubDate>
		<guid isPermaLink="false">http://regenerationstation.wordpress.com/?p=97#comment-32</guid>
		<description>To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field.  Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward).  I hope that helps - thanks for the comments!</description>
		<content:encoded><![CDATA[<p>To answer your question: I think all life science companies have been watching cell therapy for a long time. They are all trying to figure out how to profit from the field.  Some, like Invitrogen, will profit by selling tools (kits and QC assays, GMP-grade culture media and reagents, equipment) to the therapeutic companies, and others, like Celgene, BD or JNJ, will actually be looking to enter the therapeutic arena (much riskier, but more potential reward).  I hope that helps - thanks for the comments!</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on Q Therapeutics&#8217; and Invitrogen&#8217;s Symbiotic Relationship by hemato</title>
		<link>http://regeneration-station.com/2008/02/25/q-therapeutics-and-invitrogens-symbiotic-relationship/#comment-31</link>
		<dc:creator>hemato</dc:creator>
		<pubDate>Mon, 25 Feb 2008 06:23:21 +0000</pubDate>
		<guid isPermaLink="false">http://regenerationstation.wordpress.com/?p=97#comment-31</guid>
		<description>Very good analytics! 
it is pleasure to read professional opinion.
I just wondering how Invitrogen became highly interested in cell therapy and how they are going to fit in this field.
But I like their steps so far and I think they are really smart guys, including Dr. Rao</description>
		<content:encoded><![CDATA[<p>Very good analytics!<br />
it is pleasure to read professional opinion.<br />
I just wondering how Invitrogen became highly interested in cell therapy and how they are going to fit in this field.<br />
But I like their steps so far and I think they are really smart guys, including Dr. Rao</p>
]]></content:encoded>
	</item>
	<item>
		<title>Comment on FDA Proactively Addresses Embryonic Stem Cell Safety Testing by The Developing Embyronic Stem Cell Clinical Landscape &#171; The Regeneration Station</title>
		<link>http://regeneration-station.com/2007/12/31/fda-proactively-addresses-embryonic-stem-cell-safety-testing/#comment-30</link>
		<dc:creator>The Developing Embyronic Stem Cell Clinical Landscape &#171; The Regeneration Station</dc:creator>
		<pubDate>Thu, 14 Feb 2008 11:37:51 +0000</pubDate>
		<guid isPermaLink="false">http://regeneration-station.com/2007/12/31/fda-proactively-addresses-embryonic-stem-cell-safety-testing/#comment-30</guid>
		<description>[...] tissues. If any of this data becomes public, or maybe it will be part of the discussion in the FDA guidance meeting in April, it will be interesting to see how long these safety studies will be required to go out. How long [...]</description>
		<content:encoded><![CDATA[<p>[...] tissues. If any of this data becomes public, or maybe it will be part of the discussion in the FDA guidance meeting in April, it will be interesting to see how long these safety studies will be required to go out. How long [...]</p>
]]></content:encoded>
	</item>
</channel>
</rss>
